[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 39 of about 39
1. Lee JH, Kim KS, Chung CW, Park YN, Kim BR: Hepatic resection of metastatic tumor from serous cystadenocarcinoma of the ovary. J Korean Med Sci; 2002 Jun;17(3):415-8
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatic resection of metastatic tumor from serous cystadenocarcinoma of the ovary.
  • But parenchymal liver metastasis from cystic ovarian adenocarcinoma is very rare.
  • We report a case in which the resection of metastatic liver neoplasm from ovarian serous cystadenocarcinoma was done 7 yr after initial treatment.
  • On the 10th postoperative day, the patient received a single-regimen chemotherapy with paclitaxel (Taxol, 155 mg/m(2) BSA) and was discharged.
  • She has been carefully followed-up without any evidence of recurrence after completion of the remaining 5 cycles of chemo-therapy, at intervals of three weeks.
  • [MeSH-major] Cystadenocarcinoma, Serous / secondary. Cystadenocarcinoma, Serous / surgery. Liver Neoplasms / secondary. Liver Neoplasms / surgery. Ovarian Neoplasms / pathology
  • [MeSH-minor] Female. Hepatectomy. Humans. Middle Aged. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12068151.001).
  • [ISSN] 1011-8934
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC3054877
  •  go-up   go-down


2. Hiss DC, Gabriels GA, Folb PI: Combination of tunicamycin with anticancer drugs synergistically enhances their toxicity in multidrug-resistant human ovarian cystadenocarcinoma cells. Cancer Cell Int; 2007;7:5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combination of tunicamycin with anticancer drugs synergistically enhances their toxicity in multidrug-resistant human ovarian cystadenocarcinoma cells.
  • BACKGROUND: The pharmacologic modulatory effects of the antibiotic, tunicamycin (TM), on multidrug-resistant human UWOV2 ovarian cancer cells are reported.
  • The UWOV2 cell line was derived from a cystadenocarcinoma in a patient refractory to combination chemotherapy with actinomycin D, vincristine (VCR), cis-diaminedichloroplatinum (II) (CDDP) and doxorubicin (DXR).
  • In an attempt to explain drug resistance in this cell line, we examined the effects of TM on their sensitivity to various anticancer drugs, the uptake, efflux and retention of [3H]VCR, and their ability to bind [14C]DXR and [3H]azidopine (AZD), a photoaffinity label of the multidrug transporter, P-glycoprotein (Pgp).
  • The antibiotic also prolonged the intracellular retention time of [3H]VCR and increased the binding of both [14C]DXR and [3H]AZD to the cells.
  • CONCLUSION: It is concluded that the pharmacomodulatory effects of TM in these cells are mediated by global inhibition of protein and glycoprotein synthesis and synergistic interaction with antineoplastic drugs.
  • The ability of TM to enhance the sensitivity of drug resistant tumour cells may have impact on the design and optimization of novel resistance modifiers to improve the efficacy of combination treatment of intractable neoplasms.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Annu Rev Cell Dev Biol. 2002;18:1-24 [12142266.001]
  • [Cites] J Biol Chem. 2002 Oct 18;277(42):39425-35 [12176988.001]
  • [Cites] Eur J Gynaecol Oncol. 2002;23(4):337-40 [12214739.001]
  • [Cites] J Exp Ther Oncol. 2002 Jan-Feb;2(1):37-41 [12415618.001]
  • [Cites] Eur J Cancer. 2002 Nov;38(17):2309-15 [12441268.001]
  • [Cites] J Chemother. 2002 Oct;14(5):518-25 [12462432.001]
  • [Cites] Recent Results Cancer Res. 2003;161:111-6 [12528803.001]
  • [Cites] Adv Drug Deliv Rev. 2003 Jan 21;55(1):133-50 [12535578.001]
  • [Cites] J Chemother. 2005 Feb;17(1):86-95 [15828450.001]
  • [Cites] Annu Rev Biochem. 2005;74:739-89 [15952902.001]
  • [Cites] Immunol Cell Biol. 2005 Aug;83(4):429-39 [16033539.001]
  • [Cites] Hum Mol Genet. 2005 Oct 1;14(19):2787-99 [16103128.001]
  • [Cites] J Clin Invest. 2005 Oct;115(10):2656-64 [16200199.001]
  • [Cites] Cancer Res. 2005 Dec 15;65(24):11658-66 [16357177.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2006;46:189-213 [16402903.001]
  • [Cites] Curr Mol Med. 2006 Feb;6(1):55-69 [16472113.001]
  • [Cites] Curr Mol Med. 2006 Feb;6(1):111-8 [16472118.001]
  • [Cites] Neurochem Res. 2006 May;31(5):657-64 [16770736.001]
  • [Cites] J Biol Chem. 1991 Sep 5;266(25):16796-800 [1679434.001]
  • [Cites] Cancer Res. 1991 Nov 1;51(21):5915-20 [1682037.001]
  • [Cites] Annu Rev Cell Dev Biol. 2006;22:487-508 [16822172.001]
  • [Cites] Life Sci. 2006 Oct 4;79(19):1856-64 [16875701.001]
  • [Cites] Cell. 2006 Sep 8;126(5):855-67 [16959566.001]
  • [Cites] Mol Cancer Ther. 2006 Sep;5(9):2324-36 [16985067.001]
  • [Cites] Physiol Rev. 2006 Oct;86(4):1133-49 [17015486.001]
  • [Cites] Mini Rev Med Chem. 2006 Sep;6(9):1043-52 [17018003.001]
  • [Cites] Annu Rev Biochem. 2003;72:643-91 [12676797.001]
  • [Cites] Oncol Res. 2003;13(6-10):399-404 [12725530.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Aug 19;100(17):9946-51 [12902539.001]
  • [Cites] J Cell Biol. 2003 Aug 18;162(4):587-97 [12913114.001]
  • [Cites] Arzneimittelforschung. 1953 Jun;3(6):285-90 [13081480.001]
  • [Cites] Arch Gynecol Obstet. 1992;251(2):79-86 [1349803.001]
  • [Cites] J Biol Chem. 2004 Jan 2;279(1):177-87 [14561754.001]
  • [Cites] Cancer Res. 2003 Nov 1;63(21):7284-90 [14612525.001]
  • [Cites] Int J Gynecol Cancer. 2003 Nov-Dec;13(6):776-84 [14675314.001]
  • [Cites] Cell Death Differ. 2004 Apr;11(4):381-9 [14685163.001]
  • [Cites] Oncology. 1992;49(3):173-9 [1495742.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2004 Jun;286(6):E863-74 [15140753.001]
  • [Cites] Gynecol Oncol. 2004 Jul;94(1):152-60 [15262134.001]
  • [Cites] Cell Stress Chaperones. 2004 Mar;9(1):76-87 [15270080.001]
  • [Cites] Mol Pharmacol. 2004 Sep;66(3):395-403 [15322230.001]
  • [Cites] Mutat Res. 2005 Jan 6;569(1-2):29-63 [15603751.001]
  • [Cites] J Cell Physiol. 2005 Jul;204(1):45-50 [15605392.001]
  • [Cites] Mol Pharmacol. 2005 Apr;67(4):1334-41 [15662046.001]
  • [Cites] Mini Rev Med Chem. 2005 Feb;5(2):153-63 [15720285.001]
  • [Cites] Toxicol Lett. 2005 Apr 28;156(3):319-29 [15763631.001]
  • [Cites] Int J Cancer. 1999 Jan 18;80(2):279-84 [9935211.001]
  • [Cites] Cell Mol Biol (Noisy-le-grand). 1999 Feb;45(1):137-52 [10099847.001]
  • [Cites] Cell Mol Life Sci. 1999 Mar;55(3):368-422 [10228555.001]
  • [Cites] Bioessays. 1999 May;21(5):412-21 [10376012.001]
  • [Cites] Physiol Rev. 1999 Jul;79(3):683-701 [10390516.001]
  • [Cites] J Cell Biochem. 1999 Sep 15;74(4):638-47 [10440933.001]
  • [Cites] Braz J Med Biol Res. 1999 Aug;32(8):925-39 [10454753.001]
  • [Cites] J Biol Chem. 1999 Aug 27;274(35):24759-65 [10455147.001]
  • [Cites] FASEB J. 1999 Oct;13(13):1724-32 [10506575.001]
  • [Cites] Mol Biol Cell. 1999 Dec;10(12):4059-73 [10588643.001]
  • [Cites] Oncogene. 2000 May 4;19(19):2286-95 [10822379.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Oct 5;276(3):965-9 [11027576.001]
  • [Cites] FEBS J. 2007 Feb;274(3):630-58 [17288551.001]
  • [Cites] Int J Gynecol Cancer. 2007 Mar-Apr;17(2):316-24 [17362309.001]
  • [Cites] Pharmacol Ther. 1991;50(3):285-90 [1754603.001]
  • [Cites] Mod Pathol. 1990 May;3(3):298-301 [1972985.001]
  • [Cites] Am J Obstet Gynecol. 1990 Jul;163(1 Pt 1):69-73 [1973872.001]
  • [Cites] FEBS Lett. 1989 Nov 6;257(2):419-21 [2573544.001]
  • [Cites] Annu Rev Biochem. 1987;56:497-534 [3304143.001]
  • [Cites] Adv Enzyme Regul. 1984;22:27-55 [6382953.001]
  • [Cites] J Immunol Methods. 1983 Dec 16;65(1-2):55-63 [6606682.001]
  • [Cites] Pharmacol Rev. 1995 Jun;47(2):331-85 [7568331.001]
  • [Cites] Br J Cancer. 1995 Apr;71(4):670-5 [7710927.001]
  • [Cites] Anticancer Res. 1993 Jan-Feb;13(1):167-71 [8476209.001]
  • [Cites] Curr Opin Struct Biol. 1995 Oct;5(5):605-11 [8574695.001]
  • [Cites] J Biol Chem. 1996 May 24;271(21):12322-6 [8647833.001]
  • [Cites] Cancer Res. 1996 Dec 1;56(23):5309-18 [8968075.001]
  • [Cites] Carcinogenesis. 1996 Dec;17(12):2589-96 [9006093.001]
  • [Cites] Cancer Res. 1997 Feb 1;57(3):543-8 [9012488.001]
  • [Cites] Eur J Cancer. 1996 Nov;32A(12):2164-72 [9014761.001]
  • [Cites] Cancer Lett. 1997 May 19;115(2):221-7 [9149128.001]
  • [Cites] Genes Dev. 1998 Apr 1;12(7):982-95 [9531536.001]
  • [Cites] Cancer Detect Prev. 1998;22(5):455-62 [9727627.001]
  • [Cites] Biochem Biophys Res Commun. 1998 Sep 18;250(2):264-70 [9753618.001]
  • [Cites] Clin Cancer Res. 1995 Sep;1(9):935-44 [9816064.001]
  • [Cites] Melanoma Res. 1998 Oct;8(5):389-97 [9835451.001]
  • [Cites] Annu Rev Cell Dev Biol. 1998;14:459-85 [9891790.001]
  • [Cites] Adv Biochem Eng Biotechnol. 1999;64:155-201 [9933978.001]
  • [Cites] Mol Cell Biol. 2001 Feb;21(4):1249-59 [11158311.001]
  • [Cites] J Pharmacol Exp Ther. 2001 Sep;298(3):865-72 [11504778.001]
  • [Cites] Jpn J Cancer Res. 2001 Nov;92(11):1242-50 [11714450.001]
  • [Cites] Nat Rev Cancer. 2002 Jan;2(1):48-58 [11902585.001]
  • [Cites] Hematol Oncol Clin North Am. 2002 Apr;16(2):357-72, vi [12094476.001]
  • [Cites] Anal Cell Pathol. 2002;24(1):17-23 [12122280.001]
  • (PMID = 17439664.001).
  • [ISSN] 1475-2867
  • [Journal-full-title] Cancer cell international
  • [ISO-abbreviation] Cancer Cell Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1865531
  •  go-up   go-down


3. Milenković V, Sparić R, Dokić M, Petković S, Atanacković J: [Ovarian cancer after in vitro fertilization]. Srp Arh Celok Lek; 2004 Sep-Oct;132(9-10):331-3
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Ovarian cancer after in vitro fertilization].
  • There is serious concern about cancer risk in women undergoing ovarian stimulation treatment for infertility and longterm safety of these procedures.
  • Association between fertility drugs and ovarian cancer is still controversial.
  • A 30-year-old woman was referred to our institution with the initial diagnosis of an adnexal tumor after in vitro fertilization.
  • Her history revealed adnexectomy for mucinous cystadenofibroma of the left ovary eight years ago, and cystectomy due to cystadenoma of the right ovary three years ago.
  • Broad spectrum antibiotic treatment was initiated.
  • Pathological diagnosis was mucinous ovarian adenocarcinoma.
  • After the surgery, chemotherapy was applied.
  • There is an urgent need for clear interpretation of the association between fertility drugs and subsequent higher ovarian cancer risk.
  • Lacking conclusive evidence, an increased risk of ovarian cancer has been reported and more recently disputed.
  • Higher ovarian cancer risk may be serious and even life-threatening complication for women undergoing ovarian stimulation.
  • [MeSH-major] Cystadenocarcinoma, Mucinous / chemically induced. Fertility Agents, Female / adverse effects. Fertilization in Vitro / adverse effects. Ovarian Neoplasms / chemically induced

  • Genetic Alliance. consumer health - Ovarian cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15794056.001).
  • [ISSN] 0370-8179
  • [Journal-full-title] Srpski arhiv za celokupno lekarstvo
  • [ISO-abbreviation] Srp Arh Celok Lek
  • [Language] srp
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Yugoslavia
  • [Chemical-registry-number] 0 / Fertility Agents, Female
  •  go-up   go-down


Advertisement
4. Yokoyama Y, Kaji H, Kondoh H, Takeuchi E, Yamasaki Y, Inui Y: Complete response of a stage IV mucinous cystadenocarcinoma of the ovary to systemic chemotherapy employing paclitaxel and carboplatin. Gynecol Obstet Invest; 2001;52(3):210-4
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete response of a stage IV mucinous cystadenocarcinoma of the ovary to systemic chemotherapy employing paclitaxel and carboplatin.
  • BACKGROUND: The survival rate of patients with advanced-stage mucinous cystadenocarcinoma of the ovary is dismal and no best treatment is known.
  • We report a case of complete response of a stage IV mucinous cystadenocarcinoma of the ovary to systemic chemotherapy employing paclitaxel and carboplatin.
  • CASE: A 51-year-old nullipara diagnosed with International Federation of Gynecology and Obstetrics stage IV mucinous cystadenocarcinoma of the ovary underwent cytoreductive surgery followed by systemic chemotherapy employing paclitaxel and carboplatin every 4 weeks for 3 courses.
  • The patient tolerated chemotherapy well, demonstrated a remarkable response showing no evidence of malignancy at a second-look laparotomy.
  • As a consolidation chemotherapy after negative second-look laparotomy, she underwent another three courses of chemotherapy of the same regimen, and is showing no evidence of disease.
  • CONCLUSION: Paclitaxel and carboplatin may be effective in treating mucinous cystadenocarcinoma of the ovary.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cystadenocarcinoma, Mucinous / drug therapy. Ovarian Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 S. Karger AG, Basel
  • (PMID = 11598367.001).
  • [ISSN] 0378-7346
  • [Journal-full-title] Gynecologic and obstetric investigation
  • [ISO-abbreviation] Gynecol. Obstet. Invest.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


5. Doi D, Boh Y, Konishi H, Asakura H, Takeshita T: Combined chemotherapy with paclitaxel and carboplatin for mucinous cystadenocarcinoma of the ovary during pregnancy. Arch Gynecol Obstet; 2009 Oct;280(4):633-6
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined chemotherapy with paclitaxel and carboplatin for mucinous cystadenocarcinoma of the ovary during pregnancy.
  • Combined chemotherapy using carboplatin and paclitaxel has been established as a standard regimen for epithelial ovarian carcinoma.
  • We present the case of a 36-year-old woman with ovarian mucinous cystadenocarcinoma who underwent exploratory laparotomy during pregnancy, revealing Stage 1c at gestational week 15.
  • Afterwards, five courses of paclitaxel and carboplatin chemotherapy were administered biweekly from gestational week 24.
  • No recurrent or metastatic lesions were found and outcomes for both mother and neonate have been satisfactory for 40 months since diagnosis of ovarian carcinoma.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Carboplatin / therapeutic use. Cystadenocarcinoma, Mucinous / drug therapy. Ovarian Neoplasms / drug therapy. Paclitaxel / therapeutic use. Pregnancy Complications, Neoplastic / drug therapy
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols. Female. Humans. Infant, Newborn. Pregnancy

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19205713.001).
  • [ISSN] 1432-0711
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


6. Schmeler KM, Sun CC, Bodurka DC, Deavers MT, Malpica A, Coleman RL, Ramirez PT, Gershenson DM: Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum. Gynecol Oncol; 2008 Mar;108(3):510-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum.
  • OBJECTIVE: To evaluate the response of women with low-grade serous carcinoma of the ovary or peritoneum to platinum-based neoadjuvant chemotherapy.
  • METHODS: Using institutional databases, we identified 25 women with advanced low-grade serous carcinoma of the ovary or peritoneum treated with neoadjuvant platinum-based chemotherapy between 1989 and 2006.
  • RESULTS: Median patient age at diagnosis was 45 years (range 29-81).
  • The majority of patients (n=19, 76%) received a combination of a taxane and platinum drug.
  • A median of six cycles of chemotherapy was administered (range 2-16).
  • Of the 20 patients for whom pre- and post-neoadjuvant chemotherapy CA-125 levels were available, 50% had a >50% reduction after neoadjuvant chemotherapy.
  • However, radiographic survey of the 24 patients evaluable at the completion of neoadjuvant chemotherapy demonstrated one patient (4%) with a complete response, 21 (88%) with stable disease and 2 (8%) with progression following neoadjuvant chemotherapy.
  • CONCLUSIONS: The low response rate to platinum-based neoadjuvant chemotherapy observed indicates that low-grade serous carcinoma is not as responsive to conventional chemotherapy as high-grade serous carcinoma.
  • Prospective clinical trials focused specifically on low-grade serous carcinoma are needed to make meaningful advances in the treatment of this disease.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cystadenocarcinoma, Serous / drug therapy. Ovarian Neoplasms / drug therapy. Peritoneal Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Databases, Factual. Disease-Free Survival. Drug Administration Schedule. Female. Humans. Medical Records. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging. Retrospective Studies. Survival Analysis. Texas. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18155273.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


7. Storey DJ, Rush R, Stewart M, Rye T, Al-Nafussi A, Williams AR, Smyth JF, Gabra H: Endometrioid epithelial ovarian cancer : 20 years of prospectively collected data from a single center. Cancer; 2008 May 15;112(10):2211-20
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrioid epithelial ovarian cancer : 20 years of prospectively collected data from a single center.
  • BACKGROUND: Clinicopathological features and outcome of women with endometrioid and serous ovarian adenocarcinoma were compared.
  • METHODS: Between 1984 and 2004, baseline and follow-up data were prospectively recorded on 1545 patients with ovarian cancer.
  • Of these, 270 had pure endometrioid tumors; 659 had pure serous adenocarcinoma of the ovary.
  • Response to platinum-based chemotherapy (PBC) overall survival, stage-for-stage median progression-free survival (PFS), and cause-specific median survival were compared.
  • RESULTS: Median age of diagnosis for patients with endometrioid tumors was younger than those with serous adenocarcinoma of the ovary (60 years vs 62 years; P = .013).
  • Patients with concurrent endometrioid ovarian and endometrial malignancies had a survival advantage compared with those with ovarian malignancies alone.
  • Independent predictors of survival after PBC were histological type, debulking status, and disease stage.
  • CONCLUSIONS: Despite similar PBC response rates, endometrioid histology is associated with better survival compared with serous adenocarcinoma of the ovary, even with stage III or poorly differentiated tumors.
  • [MeSH-major] Cystadenocarcinoma, Serous / pathology. Endometrial Neoplasms / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Follow-Up Studies. Humans. Middle Aged. Organoplatinum Compounds / therapeutic use. Prospective Studies. Survival Rate


8. Domoto H, Mano Y, Kita T, Kikuchi Y, Sato K, Aida S, Tamai S: Chondrosarcomatous differentiation in metastatic deposit of serous papillary cystadenocarcinoma. Pathol Int; 2000 Jun;50(6):497-501
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chondrosarcomatous differentiation in metastatic deposit of serous papillary cystadenocarcinoma.
  • A rare case of serous papillary cystadenocarcinoma of the ovary showing chondrosarcomatous differentiation in a metastatic deposit late in the clinical course is reported.
  • A 49-year-old female underwent a total abdominal hysterectomy with bilateral salpingo-oophorectomy for bilateral ovarian tumors.
  • Histological diagnosis was serous papillary cystadenocarcinoma of both ovaries with lymph node metastasis.
  • After six courses of chemotherapy, she was confirmed to be in complete remission following a second laparotomy.
  • Following additional chemotherapy, a third laparotomy disclosed swollen left inguinal lymph nodes.
  • In one of these nodes, approximately 5.0 cm in greatest diameter, the predominant histological features were: chondrosarcoma of the bone and soft tissue, with small foci of serous papillary adenocarcinoma and squamous epithelium.
  • [MeSH-major] Chondrosarcoma / pathology. Cystadenocarcinoma, Papillary / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Cell Differentiation. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Keratins / analysis. Lymphatic Metastasis. Middle Aged. Mucin-1 / analysis. S100 Proteins / analysis. Vimentin / analysis

  • Genetic Alliance. consumer health - Papillary cystadenocarcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10886727.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] AUSTRALIA
  • [Chemical-registry-number] 0 / Mucin-1; 0 / S100 Proteins; 0 / Vimentin; 68238-35-7 / Keratins
  •  go-up   go-down


9. Spörri S, Chopra V, Egger N, Hawkins HK, Motamedi M, Dreher E, Schneider H: Effects of 5-aminolaevulinic acid on human ovarian cancer cells and human vascular endothelial cells in vitro. J Photochem Photobiol B; 2001 Nov 1;64(1):8-20
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of 5-aminolaevulinic acid on human ovarian cancer cells and human vascular endothelial cells in vitro.
  • Results are reported on the cellular effects and the sensitivity of cultured tumor epithelial cells (TEC) derived from human ovarian cystadenocarcinoma and human umbilical vein-derived endothelial cells (HUVEC) to exogenous 5-aminolaevulinic acid (ALA) and ALA-induced photodynamic therapy (PDT).
  • ALA-induced protoporphyrin IX (PpIX) accumulation in TEC was associated with a concentration and time-dependent significant decrease in mitochondrial activity, increase in cell membrane permeability, and dark toxicity.
  • These results indicate a potential clinical value for the use of ALA-mediated PDT to treat minimal residual disease in mucinous ovarian carcinoma.
  • [MeSH-major] Aminolevulinic Acid / toxicity. Endothelium, Vascular / drug effects. Ovarian Neoplasms / pathology. Photosensitizing Agents / toxicity
  • [MeSH-minor] Cell Membrane Permeability / drug effects. Cell Survival / drug effects. Cells, Cultured. Cystadenocarcinoma, Mucinous / pathology. Dose-Response Relationship, Drug. Epithelial Cells / drug effects. Epithelial Cells / ultrastructure. Female. Humans. Kinetics. Light. Mitochondria / drug effects. Mitochondria / metabolism. Protoporphyrins / metabolism. Reactive Oxygen Species / metabolism. Tumor Cells, Cultured. Umbilical Veins

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11705725.001).
  • [ISSN] 1011-1344
  • [Journal-full-title] Journal of photochemistry and photobiology. B, Biology
  • [ISO-abbreviation] J. Photochem. Photobiol. B, Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 0 / Protoporphyrins; 0 / Reactive Oxygen Species; 553-12-8 / protoporphyrin IX; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


10. Parker LP, Ramirez PT, Broaddus R, Sightler S, Wolf JK: Low-grade ovarian cancer in an adolescent patient. Gynecol Oncol; 2001 Jan;80(1):104-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low-grade ovarian cancer in an adolescent patient.
  • BACKGROUND: Ovarian tumors in the pediatric population are most likely to be of germ cell origin.
  • CASE: A 14-year-old girl was diagnosed with stage IIIc low-grade ovarian cancer.
  • Five months after completing standard chemotherapy, she developed recurrent disease, which progressed despite hormonal therapy.
  • She then developed toxicity on liposomal doxorubicin (Doxil) and is now receiving hospice care.
  • CONCLUSION: Low-grade serous adenocarcinoma of the ovary can present as advanced disease and should be considered in the differential diagnosis of an ovarian mass in an adolescent patient.
  • [MeSH-major] Cystadenocarcinoma, Serous / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adolescent. Female. Humans. Neoplasm Recurrence, Local / drug therapy

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 Academic Press.
  • (PMID = 11136580.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


11. Gershenson DM, Sun CC, Lu KH, Coleman RL, Sood AK, Malpica A, Deavers MT, Silva EG, Bodurka DC: Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary. Obstet Gynecol; 2006 Aug;108(2):361-8
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary.
  • OBJECTIVE: To analyze the clinical behavior of patients with stage II-IV low-grade serous carcinoma of the ovary seen at our institution who underwent primary surgery followed by platinum-based chemotherapy.
  • METHODS: Patients with stage II-IV low-grade serous carcinoma of the ovary from 1978 to 2003 were identified using existing databases.
  • Response rate to platinum-based chemotherapy in 10 evaluable patients (15% of patients with gross residual disease) was 80%, and 42 patients underwent second-look surgery: microscopically negative findings, 2 (5%); microscopically positive disease, 13 (33%); macroscopically positive disease, 24 (62%); and insufficient information, 3 (7%).
  • Median progression-free survival and overall survival times were 19.5 and 81.8 months.
  • Persistent disease after primary chemotherapy was the only factor associated with shorter overall survival time (hazard ratio 3.46, 95% confidence interval 2.00-5.97, P<.001).
  • CONCLUSION: Metastatic low-grade serous carcinoma of the ovary is characterized by young age at diagnosis and prolonged overall survival.
  • Segregating women with this diagnosis in future clinical trials is warranted.
  • [MeSH-major] Cystadenocarcinoma, Papillary / mortality. Cystadenocarcinoma, Papillary / therapy. Ovarian Neoplasms / mortality. Ovarian Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Cisplatin / administration & dosage. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Disease-Free Survival. Female. Humans. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. Survival Analysis. Texas / epidemiology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16880307.001).
  • [ISSN] 0029-7844
  • [Journal-full-title] Obstetrics and gynecology
  • [ISO-abbreviation] Obstet Gynecol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


12. Kodama M, Kawaguchi H, Komoto Y, Takemura M: Coexistent intramedullary spinal cord and choroidal metastases in ovarian cancer. J Obstet Gynaecol Res; 2010 Feb;36(1):199-203
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Coexistent intramedullary spinal cord and choroidal metastases in ovarian cancer.
  • Involvement of intramedullary spinal cord and the choroid by ovarian cancer is rare, and coexistence of metastases at these sites is extremely rare and has never been reported.
  • This condition rapidly progresses to a neurological emergency; however, an efficient standard treatment method is not available for this rare condition.
  • The case presented herein is of a female patient with stage II, poorly differentiated serous cystadenocarcinoma of the ovary.
  • She presented with blindness and other neurologic complaints during the course of treatment for a recurrence at 50 months after the primary surgical treatment for the tumor.
  • Neurological emergency was prevented by administering whole-brain irradiation therapy followed by systemic chemotherapy.
  • Early diagnosis and multidisciplinary treatment, including radiotherapy and chemotherapy, may offer good palliation for such unusual metastases of ovarian cancer.
  • [MeSH-major] Brain Neoplasms / secondary. Choroid Neoplasms / secondary. Cystadenocarcinoma, Serous / secondary. Neoplasm Recurrence, Local. Ovarian Neoplasms / pathology. Spinal Cord Neoplasms / secondary
  • [MeSH-minor] Abdominal Neoplasms / secondary. Abdominal Neoplasms / therapy. Aged, 80 and over. Combined Modality Therapy. Female. Humans. Hysterectomy. Ovariectomy

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20178552.001).
  • [ISSN] 1447-0756
  • [Journal-full-title] The journal of obstetrics and gynaecology research
  • [ISO-abbreviation] J. Obstet. Gynaecol. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


13. Lackman F, Carey MS, Kirk ME, McLachlin CM, Elit L: Surgery as sole treatment for serous borderline tumors of the ovary with noninvasive implants. Gynecol Oncol; 2003 Aug;90(2):407-12
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgery as sole treatment for serous borderline tumors of the ovary with noninvasive implants.
  • OBJECTIVES: The objectives were to describe the clinical characteristics and prognosis of surgically treated patients with stage II and III serous borderline tumors of the ovary with noninvasive implants.
  • MATERIALS AND METHODS: From 1990 to 2000, 16 patients with stage II and III ovarian serous borderline tumors and noninvasive implants were diagnosed and prospectively followed at our center.
  • All patients underwent surgical treatment including staging and their pathology was reviewed.
  • No patient was treated with adjuvant therapy (radiation or chemotherapy) after surgical treatment and none were lost to follow-up.
  • RESULTS: The mean age at diagnosis was 42 years (range 26-59).
  • Fifteen of 16 patients had ovarian surface involvement with tumor.
  • All patients but 2 had clinical evidence of extraovarian disease at the time of surgery.
  • Two patients have been treated with chemotherapy (paclitaxel/carboplatin) for progressive borderline disease, while an additional patient was treated after first relapse with chemotherapy for an invasive recurrence.
  • CONCLUSIONS: Carefully staged patients with advanced serous borderline tumors of the ovary and noninvasive implants have a good prognosis without adjuvant therapy.
  • [MeSH-major] Cystadenocarcinoma, Serous / surgery. Ovarian Neoplasms / surgery
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carboplatin / administration & dosage. Cohort Studies. Female. Humans. Middle Aged. Neoplasm Staging. Paclitaxel / administration & dosage. Prospective Studies

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12893209.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


14. Atallah D, Checrallah A, Rouzier R, Ghossain MA, Chahine G: Retroperitoneal lymphangioleiomyoma mimicking ovarian tumor emerging after tamoxifen therapy. Obstet Gynecol; 2006 Sep;108(3 Pt 2):762-4
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retroperitoneal lymphangioleiomyoma mimicking ovarian tumor emerging after tamoxifen therapy.
  • A thoraco-abdominopelvic enhanced computed tomography scan showed a 22 x 21 x 12 cm well-encapsulated, complex pelvic mass.
  • An ovarian cystadenocarcinoma was suspected.
  • We speculate that tamoxifen treatment may play a role in the development of this benign tumor.
  • [MeSH-major] Lymphangiomyoma / diagnosis. Ovarian Neoplasms. Retroperitoneal Neoplasms / diagnosis. Tamoxifen / adverse effects
  • [MeSH-minor] Adult. Breast Neoplasms / drug therapy. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Receptors, Estrogen / analysis. Receptors, Progesterone / analysis. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17018494.001).
  • [ISSN] 0029-7844
  • [Journal-full-title] Obstetrics and gynecology
  • [ISO-abbreviation] Obstet Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


15. Pusiol T, Zorzi MG, Morichetti D, Piscioli I, Scialpi M: Peritoneal Malignant Psammomatous Mesothelioma. World J Oncol; 2010 Aug;1(4):179-181

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Psammoma bodies (PBs) are observed most commonly in papillary thyroid carcinoma, meningioma, and papillary serous cystadenocarcinoma of the ovary.
  • Contrast enhanced computed tomography showed fluid diffuse in peritoneal recesses, thick septa with micronodules in the greater omentum and adjacent enhancement of the thickened peritoneum.
  • The peritoneal biopsy revealed a superficial papillary growth of malignant epithelial-like cells with diffuse involvement of submesothelial tissues.
  • The patient was treated with chemotherapy (gemcitabine, vinorelbine, cisplatin).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Tumori. 2005 Jan-Feb;91(1):1-5 [15849996.001]
  • [Cites] Am J Surg Pathol. 2000 Feb;24(2):285-94 [10680897.001]
  • [Cites] Hum Pathol. 2005 Apr;36(4):372-80 [15891998.001]
  • [Cites] Am J Surg Pathol. 2000 Jun;24(6):816-23 [10843283.001]
  • [Cites] Cancer. 1990 Jan 15;65(2):292-6 [2295052.001]
  • [Cites] Histopathology. 2006 Feb;48(3):223-32 [16430468.001]
  • [Cites] Arch Gynecol Obstet. 2009 Jun;279(6):931-6 [18982336.001]
  • [Cites] Acta Med Port. 2002 Sep-Oct;15(5):383-6 [12645223.001]
  • [Cites] Histopathology. 1997 May;30(5):403-18 [9181361.001]
  • [Cites] Diagn Cytopathol. 2009 Jul;37(7):534-41 [19373908.001]
  • (PMID = 29147203.001).
  • [ISSN] 1920-454X
  • [Journal-full-title] World journal of oncology
  • [ISO-abbreviation] World J Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Keywords] NOTNLM ; Malignant mesothelioma / Psammoma bodies / Psammomatous malignant mesothelioma
  •  go-up   go-down


16. Friedrich M, Poleska W, Baltzer J, Salehin D: Treatment of pseudomyxoma peritonei by intraoperative and intraperitoneal chemotherapy. J Clin Oncol; 2009 May 20;27(15_suppl):e16540

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of pseudomyxoma peritonei by intraoperative and intraperitoneal chemotherapy.
  • : e16540 Background: Pseudomyxoma peritonei occurs mostly in conjunction with the type of intestinal mucinous borderline tumour and is characterized by building up a lot of mucus pour of cells.
  • The most common tumor is the pseudomyxoma peritoneii with mucinous borderline tumours of the ovaries or with mucinous tumours of the appendix, normally without showing a rupture of the ovarian tumour pre- or intraoperatively.
  • The diagnosis of pseudomyxoma peritonei is mainly difficult and guidelines for the treatment are unknown.
  • METHODS: In the period from 1991 to 2008, 52 patients with pseudomyxoma peritonei were treated by tumour debulking and intraoperative and intraperitoneal chemotherapy with Mitoxantron (40 mg in 300 ml of NaCl over 72 hours).
  • There were the following histologies: mucinous cystadenoma of the ovary n = 29, mucinous cystadenoma of the appendix n = 10, mucinous cystadenocarcinoma n = 13.
  • CONCLUSIONS: The instillation of mitoxantron intraperitoneally and intraoperatively is an effective and safe therapy without any side effects after maximal tumour debulking of pseudomyxoma peritoneii.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960827.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Cossman J, Johnson K, Gottlieb J, Elashoff M: Gene expression profiling for prediction of treatment response. J Clin Oncol; 2004 Jul 15;22(14_suppl):9594

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression profiling for prediction of treatment response.
  • : 9594 Background: We designed a strategy for patient stratification aimed at identifying tumor gene expression profiles that predict a favorable response to chemotherapy and allow selection of patients who would most benefit from treatment.
  • METHODS: A statistical model was developed based on global gene expression analysis of samples from 119 individuals.
  • (1) Compare normal ovary and ovarian adenocarcinoma and test that gene profile as a marker set to distinguish responsive from similarly treated, non-responsive carcinomas or (2) Directly compare gene expression profiles of responders and non-responders and apply this profile to patient samples to predict outcome.
  • Samples were involved tissues from patients with ovarian cystadenocarcinoma obtained prior to treatment (n = 26) and histologically normal ovaries from controls (n = 93).
  • 85% (22/26) of the ovarian carcinoma patients were advanced (Stage III-IV) disease and all were treated with paclitaxel-carboplatin.
  • RESULTS: Gene expression profiles were identified from the normal-disease comparison and were predictive of patient response to treatment.
  • Genes can be individually weighted for their value in predicting treatment response and potentially chosen and assembled into a prognostic marker set.
  • CONCLUSION: Cross-validation of the training set of 26 ovarian cancers, gives preliminary evidence that a gene set predicts outcome.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28016714.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Yamamoto K, Oogi S, Inoue H, Kudoh K, Kita T, Kikuchi Y: Chronic administration of single weekly paclitaxel in heavily pretreated ovarian cancer patients. Curr Med Chem; 2004 Feb;11(4):425-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chronic administration of single weekly paclitaxel in heavily pretreated ovarian cancer patients.
  • Ovarian cancer patients with paclitaxel-resistance have been reported to respond to a weekly schedule of the same drug.
  • After the surgery, the tumor was diagnosed as serous cystadenocarcinoma of the ovary (stage IV) and 6 cycles of treatment consisting of cyclophosphamide, adriamycin and cisplatin (CAP) were performed.
  • The CA 125 level (8400 U/ml) rapidly declined to 150 U/ml by this CAP therapy.
  • Therefore, treatment with single weekly T was performed and CA 125 levels remained between 70-90 U/ml during 13 cycles of this therapy (progression free interval; more than 1 year).
  • Computing tomography (CT) and magnetic resonance imaging (MRI) revealed large amount of ascite and pelvic mass (9 x 7 x 7 cm), and low density area (3 x 3 cm) suggesting metastasis in right lobe of liver.
  • The tumor was diagnosed as endometrioid adenocarcinoma of the ovary, stage IV and chemotherapy with CAP was initiated on September 5, 1998.
  • Thereafter, she received treatments with gamma knife and CAP for brain metastasis.
  • Side effects by weekly T were mild and tolerable despite of long term treatment.
  • In addition, weekly T can be safely used in outpatient setting and even in patients with poor performance status (PS), and warrant long time to progression.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / therapy. Carcinoma, Endometrioid / drug therapy. Cystadenocarcinoma, Serous / drug therapy. Neoplasm Recurrence, Local / drug therapy. Ovarian Neoplasms / drug therapy. Paclitaxel / administration & dosage
  • [MeSH-minor] Adult. Cisplatin / administration & dosage. Cyclophosphamide / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Drug Administration Schedule. Drug Resistance, Neoplasm / drug effects. Fatal Outcome. Female. Humans. Middle Aged. Neoplasm, Residual / diagnosis. Neoplasm, Residual / drug therapy. Neoplasm, Residual / surgery. Reoperation

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14965223.001).
  • [ISSN] 0929-8673
  • [Journal-full-title] Current medicinal chemistry
  • [ISO-abbreviation] Curr. Med. Chem.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


19. Hafezi-Bakhtiari S, Morava-Protzner I, Burnell MJ, Reardon E, Colgan TJ: Choriocarcinoma arising in a serous carcinoma of ovary: an example of histopathology driving treatment. J Obstet Gynaecol Can; 2010 Jul;32(7):698-702
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Choriocarcinoma arising in a serous carcinoma of ovary: an example of histopathology driving treatment.
  • BACKGROUND: Choriocarcinoma within an ovarian carcinoma is exceptionally rare.
  • Nevertheless, recognition of this mixed tumour is important for administration of appropriate chemotherapy.
  • CASE: A 65-year-old woman underwent resection of an ovarian mass after presenting with a pelvic mass and breast tenderness.
  • This pathologic diagnosis led to a specific chemotherapy regimen with cisplatin, etoposide, and bleomycin, suitable for both types of malignancy.
  • CONCLUSION: Both gynaecologists and pathologists should be aware that the histopathologic classification of ovarian epithelial carcinoma and its variants, such as this one, may have an increasing role in the management of this disease.
  • [MeSH-major] Choriocarcinoma / pathology. Cystadenocarcinoma, Serous / pathology. Neoplasms, Multiple Primary / pathology. Ovarian Neoplasms / pathology

  • Genetic Alliance. consumer health - Choriocarcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20707961.001).
  • [ISSN] 1701-2163
  • [Journal-full-title] Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstétrique et gynécologie du Canada : JOGC
  • [ISO-abbreviation] J Obstet Gynaecol Can
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Canada
  •  go-up   go-down


20. Sato S, Kobayashi Y, Okuma Y, Kondo H, Kanishi Y, Saito K, Kiguchi K: Establishment and characterization of a cell-line originated from human mucinous cystadenocarcinoma of the ovary. Hum Cell; 2002 Sep;15(3):171-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Establishment and characterization of a cell-line originated from human mucinous cystadenocarcinoma of the ovary.
  • We recently established a cell line (designated 371M) derived from an ovarian mucinous cystadenocarcinoma.
  • Adjuvant chemotherapy (combined paclitaxel and carboplatin) was administered, but was ineffective, and she died about 4 months after surgery.
  • They proliferated in a monolayered sheet with doubling times of 84 h and 37 h in the 10th and 34th passages, respectively.
  • Sensitivity of 371M cells to a variety of anti-cancer drugs was examined by in vitro MTT assay, and the results suggested that CPT-11 and CDDP were more effective against 371M cells than other anti-cancer agents.
  • [MeSH-major] Camptothecin / analogs & derivatives. Cell Culture Techniques / methods. Cystadenocarcinoma, Mucinous. Ovarian Neoplasms
  • [MeSH-minor] Animals. Antigens, Tumor-Associated, Carbohydrate. Antineoplastic Agents / pharmacology. Biomarkers, Tumor. Cell Division. Cisplatin / pharmacology. Drug Screening Assays, Antitumor. Female. Humans. Karyotyping. Mice. Mice, Nude. Middle Aged. Neoplasm Transplantation. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Cellosaurus - a cell line knowledge resource. culture/stock collections - Cellosaurus - a cell line knowledge resource .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Treat Rep. 1987 Dec;71(12):1231-7 [3319135.001]
  • [Cites] Nihon Sanka Fujinka Gakkai Zasshi. 1985 Sep;37(9):1820-4 [4056530.001]
  • [Cites] Hum Cell. 1990 Mar;3(1):52-6 [2083224.001]
  • [Cites] Eur J Gynaecol Oncol. 2001;22(4):278-82 [11695809.001]
  • [Cites] Cancer Res. 1989 Sep 15;49(18):5153-61 [2548714.001]
  • [Cites] Hum Cell. 1995 Dec;8(4):189-94 [8721090.001]
  • [Cites] Gynecol Oncol. 1991 Feb;40(2):118-28 [2010102.001]
  • [Cites] Eur J Cancer Clin Oncol. 1982 Nov;18(11):1069-74 [6891650.001]
  • [Cites] Hum Cell. 1997 Sep;10(3):199-208 [9436040.001]
  • [Cites] Cancer Res. 1993 Jul 1;53(13):3103-8 [8319218.001]
  • [Cites] Hum Cell. 1999 Dec;12(4):211-7 [10834108.001]
  • [Cites] Cancer Res. 1985 Feb;45(2):826-32 [2981614.001]
  • [Cites] Jpn J Cancer Res. 1994 Dec;85(12):1247-56 [7852189.001]
  • [Cites] Cancer Chemother Rep. 1974 Mar-Apr;58(2):271-3 [4830501.001]
  • (PMID = 12703547.001).
  • [ISSN] 0914-7470
  • [Journal-full-title] Human cell
  • [ISO-abbreviation] Hum. Cell
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antigens, Tumor-Associated, Carbohydrate; 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0H43101T0J / irinotecan; Q20Q21Q62J / Cisplatin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


21. Sayedur Rahman M, Al-Sibai MH, Rahman J, Al-Suleiman SA, El-Yahia AR, Al-Mulhim AA, Al-Jama F: Ovarian carcinoma associated with pregnancy. A review of 9 cases. Acta Obstet Gynecol Scand; 2002 Mar;81(3):260-4
MedlinePlus Health Information. consumer health - Tumors and Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian carcinoma associated with pregnancy. A review of 9 cases.
  • BACKGROUND: The purpose of this study was to review patients with ovarian cancer in pregnancy, the effectiveness of the available methods of treatment and their prognosis.
  • METHODS: A retrospective review of all women diagnosed to have cancer of the ovary associated with pregnancy who delivered at the authors' hospitals between January 1976 and December 2000.
  • The demography, clinical presentation, time and mode of diagnosis, treatment, pregnancy outcome and maternal survival were noted.
  • RESULTS: The incidence of ovarian carcinoma in pregnancy in the series was 0.08/1000 deliveries.
  • Of the 9 patients, 7 had epithelial cancers; 4 serous cystadenocarcinoma, 2 mucinous cystadenocarcinomas and one undifferentiated cancer.
  • Three patients had total abdominal hysterectomy, bilateral salpingo-oophorectomy and omentectomy followed by chemotherapy.
  • Debulking of the tumor was done in a patient in stage III with subsequent chemotherapy.
  • This patient died 13 months from the time of diagnosis of the tumor.
  • CONCLUSIONS: Association of ovarian cancer with pregnancy is a rare occurrence.
  • Early diagnosis and appropriate treatment offers the best prognosis for the patient.
  • Aggressive postoperative chemotherapy also contributed to the better outcome.
  • [MeSH-major] Carcinoma / complications. Carcinoma / therapy. Ovarian Neoplasms / complications. Ovarian Neoplasms / therapy. Pregnancy Complications, Neoplastic / mortality. Pregnancy Complications, Neoplastic / therapy

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11966485.001).
  • [ISSN] 0001-6349
  • [Journal-full-title] Acta obstetricia et gynecologica Scandinavica
  • [ISO-abbreviation] Acta Obstet Gynecol Scand
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Denmark
  • [Number-of-references] 15
  •  go-up   go-down


22. Cormio G, Di Vagno G, Di Fazio F, Loverro G, Selvaggi L: Intramedullary spinal cord metastasis from ovarian carcinoma. Gynecol Oncol; 2001 Jun;81(3):506-8
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intramedullary spinal cord metastasis from ovarian carcinoma.
  • BACKGROUND: Intramedullary spinal cord involvement by ovarian carcinoma is extremely rare.
  • CASE: A patient with stage IV serous cystadenocarcinoma of the ovary presented with neurologic complaints 16 months after primary treatment.
  • Following chemotherapy she was given radiotherapy on the spinal cord, but died 10 months later for disseminated abdominal disease, without neurologic symptoms.
  • CONCLUSION: Spinal cord involvement is unusual in ovarian carcinoma; multidisciplinary treatment, including chemotherapy and radiotherapy, may offer good palliation of the symptomatology.
  • [MeSH-major] Cystadenocarcinoma, Serous / secondary. Ovarian Neoplasms / pathology. Spinal Cord Neoplasms / secondary
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Carboplatin / therapeutic use. Female. Humans. Middle Aged

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 Academic Press.
  • (PMID = 11371147.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; BG3F62OND5 / Carboplatin
  •  go-up   go-down


23. Heubner M, Wimberger P, Riemann K, Kasimir-Bauer S, Otterbach F, Kimmig R, Siffert W: The CYP1A1 Ile462Val polymorphism and platinum resistance of epithelial ovarian neoplasms. Oncol Res; 2010;18(7):343-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The CYP1A1 Ile462Val polymorphism and platinum resistance of epithelial ovarian neoplasms.
  • The role of estrogens in ovarian carcinogenesis and progression of ovarian cancer is unclear.
  • Cytochrome P450 is involved in estrogen metabolism, and polymorphisms have been associated with functional changes and risk for ovarian cancer.
  • In this study, we investigated the impact of the CYP1A1 Ile462Val polymorphism upon tumor risk and disease progression in ovarian cancer patients.
  • One hundred and eleven ovarian cancer patients who had been treated at the University Hospital of Essen between 1999 and 2007 and 119 age-matched healthy female controls were enrolled in this study.
  • The distribution of genotypes was statistically significant different between ovarian cancer patients and healthy controls.
  • We observed a significant association of the Ile allele with ovarian cancer (OR 2.6, 95% CI 1.5-4.7, p = 0.001).
  • Clinical parameters such as overall survival, FIGO stage, grading, and age at diagnosis did not differ significantly.
  • We observed a statistically significant association between the 462Val allele and platinum resistance, which was defined as a time interval < 6 months to disease progression after administration of a platinum-based primary chemotherapy (OR 5.9, 95% CI 1.5-23.2, p = 0.005).
  • We observed a significant association between the presence of the 462Ile allele with ovarian cancer.
  • While there is uncertainty about the potential involvement of CYP1A1 in the metabolism of platinum-containing agents, our findings suggest an association between the 462Val allele and the development of platinum resistance in ovarian tumors.
  • If confirmed in a larger, independent collective, our findings would have important relevance with respect to the clinical consequences for the primary chemotherapy of ovarian cancer patients.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Cytochrome P-450 CYP1A1 / genetics. Drug Resistance, Neoplasm / genetics. Organoplatinum Compounds / therapeutic use. Ovarian Neoplasms / genetics. Polymorphism, Genetic / genetics
  • [MeSH-minor] Adenocarcinoma, Clear Cell / drug therapy. Adenocarcinoma, Clear Cell / genetics. Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Mucinous / drug therapy. Adenocarcinoma, Mucinous / genetics. Adenocarcinoma, Mucinous / pathology. Adult. Aged. Aged, 80 and over. Case-Control Studies. Cystadenocarcinoma, Serous / drug therapy. Cystadenocarcinoma, Serous / genetics. Cystadenocarcinoma, Serous / pathology. Endometrial Neoplasms / drug therapy. Endometrial Neoplasms / genetics. Endometrial Neoplasms / pathology. Female. Genotype. Humans. Middle Aged. Ovary / metabolism. Ovary / pathology. Polymerase Chain Reaction. Polymorphism, Restriction Fragment Length. Prognosis. Survival Rate. Young Adult

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20377136.001).
  • [ISSN] 0965-0407
  • [Journal-full-title] Oncology research
  • [ISO-abbreviation] Oncol. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organoplatinum Compounds; EC 1.14.14.1 / Cytochrome P-450 CYP1A1
  •  go-up   go-down


24. Shah JP, Bryant CS, Kumar S, Ali-Fehmi R, Morris RT: Successful pregnancy after fertility-sparing surgery for peritoneal psammocarcinoma: a case report. J Reprod Med; 2009 Mar;54(3):179-83
Genetic Alliance. consumer health - Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Psammocarcinoma is a rare form of low grade serous carcinoma of the ovary or peritoneum.
  • Following fertility-sparing surgery and adjuvant chemotherapy, she was able to achieve a successful pregnancy.
  • Fifteen years after initial conservative treatment, she remains without pathologic evidence of cancer.
  • Pregnancy after the diagnosis and treatment of psammocarcinoma may not alter the clinical course of the disease.
  • [MeSH-major] Cystadenocarcinoma, Serous / surgery. Peritoneal Neoplasms / surgery
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant. Female. Humans. Neoplasm Recurrence, Local. Pregnancy. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19370904.001).
  • [ISSN] 0024-7758
  • [Journal-full-title] The Journal of reproductive medicine
  • [ISO-abbreviation] J Reprod Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Schmeler KM, Gershenson DM: Low-grade serous ovarian cancer: a unique disease. Curr Oncol Rep; 2008 Nov;10(6):519-23
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low-grade serous ovarian cancer: a unique disease.
  • Low-grade serous carcinomas represent approximately 10% of all serous ovarian carcinomas.
  • A growing body of research has demonstrated several important differences between the clinical and molecular characteristics of these tumors and those of high-grade serous ovarian carcinomas.
  • Patients with low-grade serous ovarian tumors are diagnosed at a younger age, have a longer overall survival, and have lower response rates to conventional chemotherapy.
  • In addition, low-grade serous ovarian carcinomas have pathologic and molecular characteristics distinct from high-grade serous carcinomas, yet similar to serous tumors of low malignant potential.
  • Further study, focusing specifically on low-grade serous carcinomas, is needed to determine the role of other chemotherapeutic agents, hormonal therapy, or targeted biologic agents in the treatment of this disease.
  • [MeSH-major] Cystadenocarcinoma, Serous / diagnosis. Medical Oncology / methods. Ovarian Neoplasms / diagnosis
  • [MeSH-minor] Age Factors. Antineoplastic Agents / pharmacology. Antineoplastic Agents / therapeutic use. Drug Resistance, Neoplasm. Female. Humans. Neoadjuvant Therapy / methods. Ovary / pathology. Recurrence. Treatment Outcome

  • Genetic Alliance. consumer health - Ovarian cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 1998 Jul;70(1):2-12 [9698465.001]
  • [Cites] Int J Gynecol Pathol. 1990;9(2):110-21 [2332269.001]
  • [Cites] Am J Surg Pathol. 2005 Aug;29(8):1034-41 [16006797.001]
  • [Cites] Clin Cancer Res. 2004 Oct 1;10(19):6432-6 [15475429.001]
  • [Cites] Clin Cancer Res. 2005 Oct 15;11(20):7273-9 [16243797.001]
  • [Cites] Gynecol Oncol. 2007 Apr;105(1):248-51 [17222893.001]
  • [Cites] Histopathology. 2007 May;50(6):773-9 [17493241.001]
  • [Cites] Int J Gynecol Pathol. 2004 Jul;23(3):200-5 [15213595.001]
  • [Cites] Gynecol Oncol. 2008 Mar;108(3):510-4 [18155273.001]
  • [Cites] Cancer. 2001 Jun 15;91(12):2329-34 [11413522.001]
  • [Cites] Gynecol Oncol. 2003 Jul;90(1):163-9 [12821358.001]
  • [Cites] Hum Pathol. 1988 Sep;19(9):1030-5 [3417288.001]
  • [Cites] Cancer. 1998 Mar 1;82(5):893-901 [9486579.001]
  • [Cites] Anal Quant Cytol Histol. 1986 Dec;8(4):354-7 [3814303.001]
  • [Cites] Int J Gynecol Pathol. 2003 Jan;22(1):37-41 [12496696.001]
  • [Cites] Oncogene. 2005 Feb 3;24(6):1053-65 [15558012.001]
  • [Cites] Am J Surg Pathol. 2005 Feb;29(2):218-24 [15644779.001]
  • [Cites] Gynecol Oncol. 2006 Nov;103(2):703-8 [16828848.001]
  • [Cites] Obstet Gynecol. 2002 Jan;99(1):3-10 [11777502.001]
  • [Cites] Gynecol Oncol. 2007 Jun;105(3):625-9 [17320156.001]
  • [Cites] Mol Carcinog. 2003 Feb;36(2):53-9 [12557260.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Am J Pathol. 2002 Apr;160(4):1223-8 [11943707.001]
  • [Cites] Int J Gynecol Pathol. 2007 Oct;26(4):404-9 [17885490.001]
  • [Cites] Obstet Gynecol. 2006 Aug;108(2):361-8 [16880307.001]
  • [Cites] Int J Gynecol Cancer. 2007 May-Jun;17(3):601-6 [17504374.001]
  • [Cites] Am J Surg Pathol. 2004 Apr;28(4):496-504 [15087669.001]
  • [Cites] Gynecol Oncol. 2005 Jan;96(1):259-62 [15589614.001]
  • [Cites] Gynecol Oncol. 2005 Nov;99(2):510-1 [16051342.001]
  • [Cites] Cancer Res. 2005 Nov 15;65(22):10602-12 [16288054.001]
  • [Cites] J Natl Cancer Inst. 2003 Mar 19;95(6):484-6 [12644542.001]
  • [Cites] Int J Gynecol Pathol. 1989;8(2):147-55 [2714932.001]
  • [Cites] Int J Gynecol Pathol. 2000 Jan;19(1):7-15 [10638449.001]
  • (PMID = 18928667.001).
  • [ISSN] 1534-6269
  • [Journal-full-title] Current oncology reports
  • [ISO-abbreviation] Curr Oncol Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 35
  •  go-up   go-down


26. Kaku M, Ohara N, Seima Y, Imanishi K, Tomura N, Kobayashi A, Yamasaki M, Hirata Y, Murao S: A primary retroperitoneal serous cystadenocarcinoma with clinically aggressive behavior. Arch Gynecol Obstet; 2004 Dec;270(4):302-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A primary retroperitoneal serous cystadenocarcinoma with clinically aggressive behavior.
  • CASE REPORT: We describe a 44-year-old woman with a primary retroperitoneal serous cystadenocarcinoma as the fourth report in the world literature.
  • Pathological examination showed a well-differentiated papillary serous cystadenocarcinoma of ovarian type and locoregional lymph node metastases.
  • Seven months after surgery, the patient developed a pelvic recurrence, and underwent a total hysterectomy, a left salpingo-oophorectomy and a resection of the metastatic mesenteric mass.
  • CONCLUSION: The present case illustrates the clinically aggressive nature of a primary retroperitoneal serous cystadenocarcinoma.
  • [MeSH-major] Cystadenocarcinoma, Serous / diagnosis. Retroperitoneal Neoplasms / diagnosis
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Antineoplastic Agents, Phytogenic / therapeutic use. CA-125 Antigen / blood. CA-19-9 Antigen / blood. Carboplatin / therapeutic use. Female. Humans. Liver Neoplasms / blood. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Magnetic Resonance Imaging. Mesentery. Neoplasm Recurrence, Local / surgery. Pelvic Neoplasms / secondary. Taxoids / therapeutic use. Tomography, X-Ray Computed

  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14551796.001).
  • [ISSN] 0932-0067
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Phytogenic; 0 / CA-125 Antigen; 0 / CA-19-9 Antigen; 0 / Taxoids; 15H5577CQD / docetaxel; BG3F62OND5 / Carboplatin
  •  go-up   go-down


29. Palmer JE, Sant Cassia LJ, Irwin CJ, Morris AG, Rollason TP: The prognostic value of nuclear morphometric analysis in serous ovarian carcinoma. Int J Gynecol Cancer; 2008 Jul-Aug;18(4):692-701
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The prognostic value of nuclear morphometric analysis in serous ovarian carcinoma.
  • The objective of this study was to determine whether nuclear morphometric data can predict survival, disease progression, and chemotherapeutic response in ovarian serous carcinoma.
  • Clinicopathologic and morphometric parameters were evaluated as to their individual and independent prognostic value and prediction of chemotherapy response.
  • Grade, stage, extent of disease residuum, presence of ascites, SDNA, NP, NL, NB, and orthoferet were found to be significant predictors of chemotherapy response.
  • NL (P = 0.041) and extent of residual disease (P = 0.003) were the strongest predictors of chemotherapy response with correct classification rates of 68.8% and 70.3%, respectively.
  • Results also suggest that nuclear morphometry can provide significant information to predict chemotherapy response in platinum-treated serous ovarian cancer.
  • [MeSH-major] Cell Nucleus / pathology. Cystadenocarcinoma, Serous / diagnosis. Cystadenocarcinoma, Serous / pathology. Ovarian Neoplasms / diagnosis. Ovarian Neoplasms / pathology. Ovary / ultrastructure
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cell Size. Diagnostic Techniques, Obstetrical and Gynecological. Female. Humans. Middle Aged. Neoplasm Staging. Predictive Value of Tests. Prognosis. Reproducibility of Results. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17944918.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


30. Kuscu E, Oktem M, Haberal A, Erkanli S, Bilezikci B, Demirhan B: Management of advanced-stage primary carcinoma of the fallopian tube: case report and literature review. Eur J Gynaecol Oncol; 2003;24(6):557-60
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • TVS demonstrated a 35 x 25 mm heterogeneous mass that was not clearly separated from the left ovary, and another 31 x 14 mm cystic septated lesion in the left ovary region.
  • The definitive histopathological diagnosis was primary serous adenocarcinoma of the fallopian tube with six of 25 lymph node biopsies showing metastasis.
  • Six cycles of paclitaxel (175 mg/m2) plus cisplatin (75 mg/m2) combinatin chemotherapy were administered with 3-week intervals between cycles.
  • At the time of writing 12 months after the second-look laparotomy, she was still disease-free.
  • [MeSH-major] Cystadenocarcinoma, Serous / diagnosis. Fallopian Tube Neoplasms / diagnosis. Pelvic Neoplasms / diagnosis
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Aorta, Thoracic. Appendectomy. Cisplatin / administration & dosage. Diagnosis, Differential. Fallopian Tubes / surgery. Female. Humans. Hysterectomy. Lymph Nodes / surgery. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Omentum / surgery. Ovariectomy. Paclitaxel / administration & dosage. Second-Look Surgery

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14658603.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  • [Number-of-references] 40
  •  go-up   go-down


31. Trojan J, Ly A, Wei MX, Bierwagen M, Kopinski P, Pan Y, Ardourel MY, Dufour T, Shevelev A, Trojan LA, François JC, Andres C, Popiela T, Chatel M, Kasprzak H, Anthony DD, Duc HT: Antisense anti IGF-I cellular therapy of malignant tumours: immune response in cancer patients. Biomed Pharmacother; 2010 Oct;64(8):576-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antisense anti IGF-I cellular therapy of malignant tumours: immune response in cancer patients.
  • The treatment of cancer by antisense anti-IGF-I cellular therapy inducing immune response has evoked interest among many promising strategies.
  • Here, we reported some results obtained from patients with cancer, mainly glioblastoma treated by this strategy, which was also extended to patients with colon carcinoma, ovary cystadenocarcinoma and prostate adenocarcinoma.
  • Particularly, in two treated patients with glioblastoma, the survival time was 19 and 24 months respectively in comparison to the range of 12 to 15 months observed in the case of classical treatment such as surgery, radiation or chemotherapy.
  • Furthermore, the increase in the percentage of peripheral blood monomorphonucleated cells (PBMNCs) with effector phenotype, i.e., CD8+ CD28+ in vaccinated patients might explain their prolonged survival time.
  • [MeSH-major] Cancer Vaccines / therapeutic use. Insulin-Like Growth Factor I / genetics. Neoplasms / therapy. RNA, Antisense / genetics. Tumor Cells, Cultured

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Masson SAS. All rights reserved.
  • (PMID = 20630696.001).
  • [ISSN] 1950-6007
  • [Journal-full-title] Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie
  • [ISO-abbreviation] Biomed. Pharmacother.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antigens, CD11b; 0 / Antigens, CD28; 0 / Antigens, CD8; 0 / Cancer Vaccines; 0 / ITGAM protein, human; 0 / RNA, Antisense; 67763-96-6 / Insulin-Like Growth Factor I
  •  go-up   go-down


32. Khalifeh I, Deavers MT, Cristofanilli M, Coleman RL, Malpica A, Gilcrease MZ: Primary peritoneal serous carcinoma presenting as inflammatory breast cancer. Breast J; 2009 Mar-Apr;15(2):176-81
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Nevertheless, its recognition is important because the prognosis and treatment differ from that of primary breast cancer.
  • The patient received neoadjuvant chemotherapy for breast cancer and subsequently underwent bilateral total mastectomy and bilateral sentinel lymph node biopsy.
  • Molecular testing of tumor from the ovary and axillary lymph node showed an identical pattern of allelic loss, confirming a common origin for both tumors.
  • [MeSH-minor] Cystadenocarcinoma, Serous / pathology. Cystadenocarcinoma, Serous / surgery. Diagnosis, Differential. Fallopian Tube Neoplasms / pathology. Fallopian Tube Neoplasms / surgery. Female. Humans. Inflammation / pathology. Magnetic Resonance Imaging. Mastectomy. Middle Aged. Neoplasm Metastasis. Ovarian Neoplasms / pathology. Ovarian Neoplasms / surgery. Ovariectomy. Sentinel Lymph Node Biopsy


33. Wu M, Shen K, Lang J, Huang R, Huang H, Pan L: [Transitional cell carcinoma of the ovary: one kind of uncommon type of ovarian epithelial carcinoma]. Zhonghua Fu Chan Ke Za Zhi; 2002 Dec;37(12):733-5
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Transitional cell carcinoma of the ovary: one kind of uncommon type of ovarian epithelial carcinoma].
  • OBJECTIVE: To evaluated clinico-biologic behavior, prognosis and relative prognostic factors of transitional cell carcinoma of the ovary.
  • METHODS: The clinical records of 58 patients with transitional cell carcinoma of the ovary, who received treatment in the department of Obstetrics and Gynecology, Peking Union Medical College Hospital in 20 years, were reviewed retrospectively.
  • 31% of them had bilateral ovary involvement, and the median level of CA(125) was (687 +/- 365) U/L.
  • Different courses of chemotherapy were given to all patients.
  • The Cox hazards regression model was used to analyze the possible prognostic factors and revealed that tumor residuals (P < 0.01), preoperative level of CA(125) (P < 0.01), bilateral ovary involvement (P < 0.05) and lymph node metastasis (P < 0.05) were the most important prognostic factors.
  • CONCLUSIONS: Transitional cell carcinoma of ovary is an uncommon type of ovarian cancer.
  • It usually behaves better prognosis when compared with papillary serous cystadenocarcinoma of the ovary.
  • [MeSH-major] Carcinoma, Transitional Cell / mortality. Ovarian Neoplasms / mortality

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12622917.001).
  • [ISSN] 0529-567X
  • [Journal-full-title] Zhonghua fu chan ke za zhi
  • [ISO-abbreviation] Zhonghua Fu Chan Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


34. Wong TM, Yeo W, Chan LW, Mok TS: Hemorrhagic pyelitis, ureteritis, and cystitis secondary to cyclophosphamide: case report and review of the literature. Gynecol Oncol; 2000 Feb;76(2):223-5
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Hemorrhagic cystitis is a well-known complication of cyclophosphamide therapy but extensive involvement of the entire urinary tract is far less common.
  • We report here a patient who developed severe hemorrhagic pyelitis, ureteritis, and cystitis after one cycle of cyclophosphamide-containing combination chemotherapy.
  • METHOD: A patient with synchronous carcinoma of the ovary and the uterus developed severe hemorrhagic pyelitis, ureteritis, and cystitis leading to bilateral hydronephroses and acute renal failure after one cycle of combination chemotherapy containing cyclophosphamide.
  • Prompt diagnosis and intervention may be life-saving.
  • [MeSH-minor] Carcinoma, Endometrioid / drug therapy. Cystadenocarcinoma, Serous / drug therapy. Endometrial Neoplasms / drug therapy. Female. Humans. Middle Aged. Ovarian Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Bleeding.
  • MedlinePlus Health Information. consumer health - Ureteral Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 Academic Press.
  • (PMID = 10637075.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


35. Ferrandina G, Stoler A, Fagotti A, Fanfani F, Sacco R, De Pasqua A, Mancuso S, Scambia G: p21WAF1/CIP1 protein expression in primary ovarian cancer. Int J Oncol; 2000 Dec;17(6):1231-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p21WAF1/CIP1 protein expression in primary ovarian cancer.
  • p21WAF1/CIP1 protein is a cyclin-dependent kinase inhibitor, able to prevent the CDK2/cyclin E induced retinoblastoma protein (pRB) phosphorylation, thus inhibiting cell cycle progression at G1 phase. p21WAF1/CIP1 protein levels were examined in a series of 102 ovarian tissue samples including normal ovary, primary ovarian tumors, omental metastasis, recurrent disease and residual tumor after chemotherapy exposure, by Western blot analysis.
  • The association of p21WAF1/CIP1 status with clinicopathological parameters and clinical outcome was also investigated. p21WAF1/CIP1 protein was detectable in 76 out of 102 (74%) ovarian tissue samples.
  • We observed a significant trend of p21 levels to gradually increase from normal ovarian tissues (median 0 a.u.) through primary ovarian cancers (median 0.19 a.u.
  • In the group of stage III-IV ovarian cancer patients, p21-positive cases showed a more favourable prognosis with respect to p21-negative cases: the 3-year time to progression (TTP) rate was 58% for p21-positive compared with 33% of p21-negative cases (p=0.036).
  • In conclusion, p21WAF1/CIP1 expression levels seem to be correlated with tumor status at the time of diagnosis and can predict TTP in a selected group of patients.
  • [MeSH-major] Cyclins / biosynthesis. Cystadenocarcinoma, Serous / metabolism. Gene Expression Regulation, Neoplastic. Neoplasm Proteins / biosynthesis. Ovarian Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Endometrioid / drug therapy. Carcinoma, Endometrioid / genetics. Carcinoma, Endometrioid / metabolism. Carcinoma, Endometrioid / pathology. Carcinoma, Endometrioid / secondary. Carcinoma, Endometrioid / surgery. Cell Cycle. Cisplatin / administration & dosage. Cyclin-Dependent Kinase Inhibitor p21. Cystadenocarcinoma, Mucinous / drug therapy. Cystadenocarcinoma, Mucinous / genetics. Cystadenocarcinoma, Mucinous / metabolism. Cystadenocarcinoma, Mucinous / pathology. Cystadenocarcinoma, Mucinous / secondary. Cystadenocarcinoma, Mucinous / surgery. Disease Progression. Female. Genes, p53. Humans. Life Tables. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Neoplasm, Residual. Omentum. Ovary / metabolism. Peritoneal Neoplasms / metabolism. Peritoneal Neoplasms / secondary. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11078810.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] GREECE
  • [Chemical-registry-number] 0 / CDKN1A protein, human; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Cyclins; 0 / Neoplasm Proteins; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


36. Veroni S, Terzopoulou K, Anagnostopoulou I, Vassilakaki T, Grammatoglou X, Rammou R: Extraovarian peritoneal serous papillary carcinoma: a case report. Acta Cytol; 2010 Sep-Oct;54(5 Suppl):879-84

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Extraovarian peritoneal serous papillary carcinoma (EPSPC) is a rare cancer closely related to ovarian carcinoma and characterized by abdominal carcinomatosis without an identifiable abdominal primary tumor.
  • The histologic and immunohistochemical study of peritoneal biopsy specimens resulted in the diagnosis of EPSPC.
  • CONCLUSION: The combination of cytology, histology, immunohistochemistry and clinical data is a reliable method for the preoperative diagnosis of EPSPC, allowing prompt chemotherapy as surgery may not be indicated in most cases.
  • [MeSH-major] Carcinoma, Papillary / pathology. Cystadenocarcinoma, Serous / pathology. Ovary / pathology. Peritoneal Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21053561.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neoplasm Proteins
  •  go-up   go-down


37. Köbel M, Kalloger SE, Carrick J, Huntsman D, Asad H, Oliva E, Ewanowich CA, Soslow RA, Gilks CB: A limited panel of immunomarkers can reliably distinguish between clear cell and high-grade serous carcinoma of the ovary. Am J Surg Pathol; 2009 Jan;33(1):14-21
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A limited panel of immunomarkers can reliably distinguish between clear cell and high-grade serous carcinoma of the ovary.
  • The distinction of ovarian clear cell carcinomas (CCCs) from high-grade serous carcinomas (HG-SCs) is sometimes a diagnostic challenge.
  • With the recognition that CCCs respond poorly to conventional chemotherapy there are efforts to initiate clinical trials for CCC, making accurate diagnosis critical.
  • The purpose of this study was to test and validate a set of antibodies that could aid in the diagnosis of CCC, using a series of cases from different centers in North America.
  • [MeSH-major] Adenocarcinoma, Clear Cell / diagnosis. Biomarkers, Tumor / analysis. Cystadenocarcinoma, Serous / diagnosis. Ovarian Neoplasms / diagnosis
  • [MeSH-minor] Area Under Curve. Diagnosis, Differential. Female. Humans. Immunohistochemistry. ROC Curve. Sensitivity and Specificity. Tissue Array Analysis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18830127.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


38. Ryu DR, Yoo TH, Kim YT, Jeong HJ, Cho NH, Kang SW: Minimal change disease in a patient with ovarian papillary serous carcinoma. Gynecol Oncol; 2004 May;93(2):554-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Minimal change disease in a patient with ovarian papillary serous carcinoma.
  • BACKGROUND: Nephrotic syndrome (NS) is rarely associated with ovarian tumor.
  • Only five cases of NS with pathologic diagnosis have been reported in patients with ovarian tumors.
  • However, the association between minimal change disease (MCD) and ovarian tumor has not been previously reported.
  • Radiologic studies revealed a 10 x 10 x 11 cm-sized mass and multiple enlarged lymph nodes, suggesting a malignant ovarian tumor.
  • Histopathology of the mass and the kidney revealed papillary serous carcinoma of the ovary and MCD, respectively.
  • Oral prednisolone and adjuvant chemotherapy resulted in remission of NS.
  • CONCLUSION: We herein report a case of MCD associated with ovarian carcinoma.
  • [MeSH-major] Cystadenocarcinoma, Papillary / complications. Cystadenocarcinoma, Serous / complications. Nephrosis, Lipoid / complications. Ovarian Neoplasms / complications

  • Genetic Alliance. consumer health - Minimal change disease.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15099980.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


39. Piura B, Rabinovich A, Yanai-Inbar I: Psammomacarcinoma of the peritoneum. Eur J Obstet Gynecol Reprod Biol; 2001 Aug;97(2):231-4
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Psammomacarcinoma is a rare histologic subtype of serous carcinoma originating in the ovary or peritoneum, characterized by massive psammoma body formation, invasiveness, and low-grade differentiation.
  • Peritoneal psammomacarcinoma is even rarer than its ovarian counterpart with only 10 cases have previously been documented in the literature.
  • The patient received adjuvant chemotherapy with taxol and cisplatin, and to date, 15 months after surgery, she is alive and with no evidence of disease.
  • The mainstay of treatment is surgical debulking.
  • The role of adjuvant chemotherapy has as yet not been established.
  • [MeSH-major] Cystadenocarcinoma / diagnosis. Peritoneal Neoplasms / diagnosis
  • [MeSH-minor] Adnexa Uteri / surgery. Aged. Antineoplastic Agents / therapeutic use. Ascitic Fluid. Biomarkers, Tumor / blood. CA-125 Antigen / blood. Chemotherapy, Adjuvant. Cisplatin / therapeutic use. Female. Humans. Hysterectomy. Jejunum / surgery. Omentum / surgery. Paclitaxel / therapeutic use. Tomography, X-Ray Computed. Ultrasonography

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11451554.001).
  • [ISSN] 0301-2115
  • [Journal-full-title] European journal of obstetrics, gynecology, and reproductive biology
  • [ISO-abbreviation] Eur. J. Obstet. Gynecol. Reprod. Biol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down






Advertisement